Immunicum has received approval to extend the phase I/II-study in liver cancer by up to six patients to be treated with INTUVAX in combination with first-line treatments 16 December 2015 Read more
Immunicum has received approval to extend the phase I/II-study in liver cancer by up to six patients to be treated with INTUVAX in combination with first-line treatments 16 December 2015 Read more
Immunicum announces that the Company has received approval to start a phase I/II study in patients with gastrointestinal stromal tumor 16 December 2015 Read more
Immunicum announces that the Company has received approval to start a phase I/II study in patients with gastrointestinal stromal tumor 16 December 2015 Read more
Immunicum reports updated data from the INTUVAX phase I/II study in liver cancer and announces plan for the continuation of the study 25 November 2015 Read more
Immunicum reports updated data from the INTUVAX phase I/II study in liver cancer and announces plan for the continuation of the study 25 November 2015 Read more
Immunicum’s patent application regarding the cancer immune primer INTUVAX will be granted in Japan 20 November 2015 Read more
Immunicum's patent application regarding the cancer immune primer INTUVAX will be granted in Japan 20 November 2015 Read more
Immunicum presents continued improvement in phase I/II survival data for INTUVAX-treated renal cancer patients 17 November 2015 Read more
Immunicum presents continued improvement in phase I/II survival data for INTUVAX-treated renal cancer patients 17 November 2015 Read more
Immunicum’s patent application regarding the cancer immune primer INTUVAX will be granted in Europe 9 November 2015 Read more
Immunicum's patent application regarding the cancer immune primer INTUVAX will be granted in Europe 9 November 2015 Read more
Immunicum in collaboration with Karolinska Institute submits an application for starting a clinical study with INTUVAX® in GIST 17 September 2015 Read more
Immunicum in collaboration with Karolinska Institute submits an application for starting a clinical study with INTUVAX® in GIST 17 September 2015 Read more
Immunicum provides Ad5PTDf35 adenovirus technology to Rutgers Cancer Institute 7 September 2015 Read more
Immunicum provides Ad5PTDf35 adenovirus technology to Rutgers Cancer Institute 7 September 2015 Read more
Immunicum updates safety and survival data in phase I/II liver cancer study with INTUVAX 24 August 2015 Read more
Immunicum updates safety and survival data in phase I/II liver cancer study with INTUVAX 24 August 2015 Read more
Immunicum presents continued improvement in phase I/II survival data for INTUVAX-treated renal cancer patients 4 August 2015 Read more
Immunicum presents continued improvement in phase I/II survival data for INTUVAX-treated renal cancer patients 4 August 2015 Read more
Immunicum includes first patient in a phase II study in patients with metastatic kidney cancer 5 May 2015 Read more
Immunicum includes first patient in a phase II study in patients with metastatic kidney cancer 5 May 2015 Read more
Immunicum updates safety and survival data in liver cancer study with INTUVAX 23 April 2015 Read more
Immunicum updates safety and survival data in liver cancer study with INTUVAX 23 April 2015 Read more
Immunicum’s Chief Scientific Officer presented the technology behind the cancer vaccine INTUVAX at a symposium at Karolinska Institutet in conjunction with world-leading researchers in immunology 13 March 2015 Read more
Immunicum's Chief Scientific Officer presented the technology behind the cancer vaccine INTUVAX at a symposium at Karolinska Institutet in conjunction with world-leading researchers in immunology 13 March 2015 Read more
Immunicum receives approval to start phase II study with the therapeutic cancer vaccine INTUVAX 17 February 2015 Read more
